The management of bacteremic shock.
D058186:Acute Kidney Injury / Q000209:etiology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002056:Burns / Q000150:complications; D002404:Catheterization / Q000009:adverse effects; D002509:Cephaloridine / Q000627:therapeutic use; D002512:Cephalothin / Q000627:therapeutic use; D003428:Cross Infection; D004927:Escherichia coli Infections; D005839:Gentamicins / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D007710:Klebsiella Infections; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011113:Polymyxins / Q000627:therapeutic use; D011183:Postoperative Complications; D011512:Proteus Infections; D011552:Pseudomonas Infections; D011654:Pulmonary Edema / Q000209:etiology; D006435:Renal Dialysis / Q000009:adverse effects; D018805:Sepsis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D012756:Sheep; D012772:Shock, Septic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D013203:Staphylococcal Infections
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D005938:Glucocorticoids; D011113:Polymyxins; D010643:Phenoxybenzamine; D007612:Kanamycin; D002509:Cephaloridine; D002512:Cephalothin